Table of Content

1 Hypertension Drug Market Overview
1.1 Product Overview and Scope of Hypertension Drug
1.2 Hypertension Drug Segment by Type
1.2.1 Global Hypertension Drug Market Value Comparison by Type (2024-2034)
1.2.2 Calcium Channel Blockers
1.2.3 Diuretics
1.2.4 Beta Blockers Vasodilators
1.2.5 Angiotensin Converting Enzyme Inhibitors
1.2.6 Alpha Blockers
1.2.7 Angiotensin Receptor Blockers
1.2.8 Renin Inhibitors
1.3 Hypertension Drug Segment by Application
1.3.1 Global Hypertension Drug Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Private Clinic
1.3.4 Others
1.4 Global Hypertension Drug Market Size Estimates and Forecasts
1.4.1 Global Hypertension Drug Revenue 2018-2029
1.4.2 Global Hypertension Drug Sales 2018-2029
1.4.3 Global Hypertension Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Hypertension Drug Market Competition by Manufacturers
2.1 Global Hypertension Drug Sales Market Share by Manufacturers (2018-2024)
2.2 Global Hypertension Drug Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Hypertension Drug Average Price by Manufacturers (2018-2024)
2.4 Global Hypertension Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Hypertension Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hypertension Drug, Product Type & Application
2.7 Hypertension Drug Market Competitive Situation and Trends
2.7.1 Hypertension Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hypertension Drug Players Market Share by Revenue
2.7.3 Global Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hypertension Drug Retrospective Market Scenario by Region
3.1 Global Hypertension Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Hypertension Drug Global Hypertension Drug Sales by Region: 2018-2029
3.2.1 Global Hypertension Drug Sales by Region: 2018-2024
3.2.2 Global Hypertension Drug Sales by Region: 2024-2029
3.3 Global Hypertension Drug Global Hypertension Drug Revenue by Region: 2018-2029
3.3.1 Global Hypertension Drug Revenue by Region: 2018-2024
3.3.2 Global Hypertension Drug Revenue by Region: 2024-2029
3.4 North America Hypertension Drug Market Facts & Figures by Country
3.4.1 North America Hypertension Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Hypertension Drug Sales by Country (2018-2029)
3.4.3 North America Hypertension Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hypertension Drug Market Facts & Figures by Country
3.5.1 Europe Hypertension Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Hypertension Drug Sales by Country (2018-2029)
3.5.3 Europe Hypertension Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hypertension Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Hypertension Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Hypertension Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Hypertension Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hypertension Drug Market Facts & Figures by Country
3.7.1 Latin America Hypertension Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Hypertension Drug Sales by Country (2018-2029)
3.7.3 Latin America Hypertension Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hypertension Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Hypertension Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Hypertension Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Hypertension Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hypertension Drug Sales by Type (2018-2029)
4.1.1 Global Hypertension Drug Sales by Type (2018-2024)
4.1.2 Global Hypertension Drug Sales by Type (2024-2029)
4.1.3 Global Hypertension Drug Sales Market Share by Type (2018-2029)
4.2 Global Hypertension Drug Revenue by Type (2018-2029)
4.2.1 Global Hypertension Drug Revenue by Type (2018-2024)
4.2.2 Global Hypertension Drug Revenue by Type (2024-2029)
4.2.3 Global Hypertension Drug Revenue Market Share by Type (2018-2029)
4.3 Global Hypertension Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Hypertension Drug Sales by Application (2018-2029)
5.1.1 Global Hypertension Drug Sales by Application (2018-2024)
5.1.2 Global Hypertension Drug Sales by Application (2024-2029)
5.1.3 Global Hypertension Drug Sales Market Share by Application (2018-2029)
5.2 Global Hypertension Drug Revenue by Application (2018-2029)
5.2.1 Global Hypertension Drug Revenue by Application (2018-2024)
5.2.2 Global Hypertension Drug Revenue by Application (2024-2029)
5.2.3 Global Hypertension Drug Revenue Market Share by Application (2018-2029)
5.3 Global Hypertension Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Actelion Ltd.
6.1.1 Actelion Ltd. Corporation Information
6.1.2 Actelion Ltd. Description and Business Overview
6.1.3 Actelion Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Actelion Ltd. Hypertension Drug Product Portfolio
6.1.5 Actelion Ltd. Recent Developments/Updates
6.2 Alvogen
6.2.1 Alvogen Corporation Information
6.2.2 Alvogen Description and Business Overview
6.2.3 Alvogen Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Alvogen Hypertension Drug Product Portfolio
6.2.5 Alvogen Recent Developments/Updates
6.3 AstraZeneca Plc
6.3.1 AstraZeneca Plc Corporation Information
6.3.2 AstraZeneca Plc Description and Business Overview
6.3.3 AstraZeneca Plc Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.3.4 AstraZeneca Plc Hypertension Drug Product Portfolio
6.3.5 AstraZeneca Plc Recent Developments/Updates
6.4 Bayer AG
6.4.1 Bayer AG Corporation Information
6.4.2 Bayer AG Description and Business Overview
6.4.3 Bayer AG Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Bayer AG Hypertension Drug Product Portfolio
6.4.5 Bayer AG Recent Developments/Updates
6.5 Bellerophon Therapeutics, Inc
6.5.1 Bellerophon Therapeutics, Inc Corporation Information
6.5.2 Bellerophon Therapeutics, Inc Description and Business Overview
6.5.3 Bellerophon Therapeutics, Inc Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Bellerophon Therapeutics, Inc Hypertension Drug Product Portfolio
6.5.5 Bellerophon Therapeutics, Inc Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Boehringer Ingelheim Hypertension Drug Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Boryung Pharmaceutical Co.,Ltd
6.6.1 Boryung Pharmaceutical Co.,Ltd Corporation Information
6.6.2 Boryung Pharmaceutical Co.,Ltd Description and Business Overview
6.6.3 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product Portfolio
6.7.5 Boryung Pharmaceutical Co.,Ltd Recent Developments/Updates
6.8 Bristol-Myers Squibb and Company,
6.8.1 Bristol-Myers Squibb and Company, Corporation Information
6.8.2 Bristol-Myers Squibb and Company, Description and Business Overview
6.8.3 Bristol-Myers Squibb and Company, Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Bristol-Myers Squibb and Company, Hypertension Drug Product Portfolio
6.8.5 Bristol-Myers Squibb and Company, Recent Developments/Updates
6.9 Daiichi Sankyo Company
6.9.1 Daiichi Sankyo Company Corporation Information
6.9.2 Daiichi Sankyo Company Description and Business Overview
6.9.3 Daiichi Sankyo Company Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Daiichi Sankyo Company Hypertension Drug Product Portfolio
6.9.5 Daiichi Sankyo Company Recent Developments/Updates
6.10 Eli Lilly and Company
6.10.1 Eli Lilly and Company Corporation Information
6.10.2 Eli Lilly and Company Description and Business Overview
6.10.3 Eli Lilly and Company Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Eli Lilly and Company Hypertension Drug Product Portfolio
6.10.5 Eli Lilly and Company Recent Developments/Updates
6.11 F. Hoffmann-La Roche Ltd.
6.11.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.11.2 F. Hoffmann-La Roche Ltd. Hypertension Drug Description and Business Overview
6.11.3 F. Hoffmann-La Roche Ltd. Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.11.4 F. Hoffmann-La Roche Ltd. Hypertension Drug Product Portfolio
6.11.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.12 Gilead Sciences, Inc
6.12.1 Gilead Sciences, Inc Corporation Information
6.12.2 Gilead Sciences, Inc Hypertension Drug Description and Business Overview
6.12.3 Gilead Sciences, Inc Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.12.4 Gilead Sciences, Inc Hypertension Drug Product Portfolio
6.12.5 Gilead Sciences, Inc Recent Developments/Updates
6.13 HanAll Biopharma Co., Ltd
6.13.1 HanAll Biopharma Co., Ltd Corporation Information
6.13.2 HanAll Biopharma Co., Ltd Hypertension Drug Description and Business Overview
6.13.3 HanAll Biopharma Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.13.4 HanAll Biopharma Co., Ltd Hypertension Drug Product Portfolio
6.13.5 HanAll Biopharma Co., Ltd Recent Developments/Updates
6.14 Hanmi Pharmaceutical Co., Ltd
6.14.1 Hanmi Pharmaceutical Co., Ltd Corporation Information
6.14.2 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Description and Business Overview
6.14.3 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product Portfolio
6.14.5 Hanmi Pharmaceutical Co., Ltd Recent Developments/Updates
6.15 Johnson & Johnson Ltd
6.15.1 Johnson & Johnson Ltd Corporation Information
6.15.2 Johnson & Johnson Ltd Hypertension Drug Description and Business Overview
6.15.3 Johnson & Johnson Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Johnson & Johnson Ltd Hypertension Drug Product Portfolio
6.15.5 Johnson & Johnson Ltd Recent Developments/Updates
6.16 JW Pharmaceutical Corporation (Choongwae Pharma)
6.16.1 JW Pharmaceutical Corporation (Choongwae Pharma) Corporation Information
6.16.2 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Description and Business Overview
6.16.3 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.16.4 JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product Portfolio
6.16.5 JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments/Updates
6.17 Kyowa Kirin Co., Ltd
6.17.1 Kyowa Kirin Co., Ltd Corporation Information
6.17.2 Kyowa Kirin Co., Ltd Hypertension Drug Description and Business Overview
6.17.3 Kyowa Kirin Co., Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Kyowa Kirin Co., Ltd Hypertension Drug Product Portfolio
6.17.5 Kyowa Kirin Co., Ltd Recent Developments/Updates
6.18 Lupin Limited
6.18.1 Lupin Limited Corporation Information
6.18.2 Lupin Limited Hypertension Drug Description and Business Overview
6.18.3 Lupin Limited Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.18.4 Lupin Limited Hypertension Drug Product Portfolio
6.18.5 Lupin Limited Recent Developments/Updates
6.19 Merck & Co.
6.19.1 Merck & Co. Corporation Information
6.19.2 Merck & Co. Hypertension Drug Description and Business Overview
6.19.3 Merck & Co. Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Merck & Co. Hypertension Drug Product Portfolio
6.19.5 Merck & Co. Recent Developments/Updates
6.20 Noden Pharma DAC
6.20.1 Noden Pharma DAC Corporation Information
6.20.2 Noden Pharma DAC Hypertension Drug Description and Business Overview
6.20.3 Noden Pharma DAC Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.20.4 Noden Pharma DAC Hypertension Drug Product Portfolio
6.20.5 Noden Pharma DAC Recent Developments/Updates
6.21 Novartis AG
6.21.1 Novartis AG Corporation Information
6.21.2 Novartis AG Hypertension Drug Description and Business Overview
6.21.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.21.4 Novartis AG Hypertension Drug Product Portfolio
6.21.5 Novartis AG Recent Developments/Updates
6.22 Pfizer Inc
6.22.1 Pfizer Inc Corporation Information
6.22.2 Pfizer Inc Hypertension Drug Description and Business Overview
6.22.3 Pfizer Inc Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.22.4 Pfizer Inc Hypertension Drug Product Portfolio
6.22.5 Pfizer Inc Recent Developments/Updates
6.23 Ranbaxy Laboratories Limited
6.23.1 Ranbaxy Laboratories Limited Corporation Information
6.23.2 Ranbaxy Laboratories Limited Hypertension Drug Description and Business Overview
6.23.3 Ranbaxy Laboratories Limited Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.23.4 Ranbaxy Laboratories Limited Hypertension Drug Product Portfolio
6.23.5 Ranbaxy Laboratories Limited Recent Developments/Updates
6.24 Sanofi S.A
6.24.1 Sanofi S.A Corporation Information
6.24.2 Sanofi S.A Hypertension Drug Description and Business Overview
6.24.3 Sanofi S.A Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.24.4 Sanofi S.A Hypertension Drug Product Portfolio
6.24.5 Sanofi S.A Recent Developments/Updates
6.25 Lung Biotechnology PBC
6.25.1 Lung Biotechnology PBC Corporation Information
6.25.2 Lung Biotechnology PBC Hypertension Drug Description and Business Overview
6.25.3 Lung Biotechnology PBC Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.25.4 Lung Biotechnology PBC Hypertension Drug Product Portfolio
6.25.5 Lung Biotechnology PBC Recent Developments/Updates
6.26 Nippon Shinyaku Co. Ltd
6.26.1 Nippon Shinyaku Co. Ltd Corporation Information
6.26.2 Nippon Shinyaku Co. Ltd Hypertension Drug Description and Business Overview
6.26.3 Nippon Shinyaku Co. Ltd Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.26.4 Nippon Shinyaku Co. Ltd Hypertension Drug Product Portfolio
6.26.5 Nippon Shinyaku Co. Ltd Recent Developments/Updates
6.27 Novartis AG
6.27.1 Novartis AG Corporation Information
6.27.2 Novartis AG Hypertension Drug Description and Business Overview
6.27.3 Novartis AG Hypertension Drug Sales, Revenue and Gross Margin (2018-2024)
6.27.4 Novartis AG Hypertension Drug Product Portfolio
6.27.5 Novartis AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hypertension Drug Industry Chain Analysis
7.2 Hypertension Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hypertension Drug Production Mode & Process
7.4 Hypertension Drug Sales and Marketing
7.4.1 Hypertension Drug Sales Channels
7.4.2 Hypertension Drug Distributors
7.5 Hypertension Drug Customers
8 Hypertension Drug Market Dynamics
8.1 Hypertension Drug Industry Trends
8.2 Hypertension Drug Market Drivers
8.3 Hypertension Drug Market Challenges
8.4 Hypertension Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Hypertension Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Hypertension Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Hypertension Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Hypertension Drug Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Hypertension Drug Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Hypertension Drug Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Hypertension Drug Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Hypertension Drug Average Price (USD/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Hypertension Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Hypertension Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Hypertension Drug, Product Type & Application
Table 12. Global Key Manufacturers of Hypertension Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Hypertension Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Hypertension Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Hypertension Drug Sales Market Share by Region (2018-2024)
Table 19. Global Hypertension Drug Sales by Region (2024-2029) & (K Units)
Table 20. Global Hypertension Drug Sales Market Share by Region (2024-2029)
Table 21. Global Hypertension Drug Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Hypertension Drug Revenue Market Share by Region (2018-2024)
Table 23. Global Hypertension Drug Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Hypertension Drug Revenue Market Share by Region (2024-2029)
Table 25. North America Hypertension Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Hypertension Drug Sales by Country (2018-2024) & (K Units)
Table 27. North America Hypertension Drug Sales by Country (2024-2029) & (K Units)
Table 28. North America Hypertension Drug Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Hypertension Drug Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Hypertension Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Hypertension Drug Sales by Country (2018-2024) & (K Units)
Table 32. Europe Hypertension Drug Sales by Country (2024-2029) & (K Units)
Table 33. Europe Hypertension Drug Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Hypertension Drug Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Hypertension Drug Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Hypertension Drug Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Hypertension Drug Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Hypertension Drug Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Hypertension Drug Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Hypertension Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Hypertension Drug Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Hypertension Drug Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Hypertension Drug Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Hypertension Drug Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Hypertension Drug Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Hypertension Drug Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Hypertension Drug Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Hypertension Drug Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Hypertension Drug Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Hypertension Drug Sales (K Units) by Type (2018-2024)
Table 51. Global Hypertension Drug Sales (K Units) by Type (2024-2029)
Table 52. Global Hypertension Drug Sales Market Share by Type (2018-2024)
Table 53. Global Hypertension Drug Sales Market Share by Type (2024-2029)
Table 54. Global Hypertension Drug Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Hypertension Drug Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Hypertension Drug Revenue Market Share by Type (2018-2024)
Table 57. Global Hypertension Drug Revenue Market Share by Type (2024-2029)
Table 58. Global Hypertension Drug Price (USD/Unit) by Type (2018-2024)
Table 59. Global Hypertension Drug Price (USD/Unit) by Type (2024-2029)
Table 60. Global Hypertension Drug Sales (K Units) by Application (2018-2024)
Table 61. Global Hypertension Drug Sales (K Units) by Application (2024-2029)
Table 62. Global Hypertension Drug Sales Market Share by Application (2018-2024)
Table 63. Global Hypertension Drug Sales Market Share by Application (2024-2029)
Table 64. Global Hypertension Drug Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Hypertension Drug Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Hypertension Drug Revenue Market Share by Application (2018-2024)
Table 67. Global Hypertension Drug Revenue Market Share by Application (2024-2029)
Table 68. Global Hypertension Drug Price (USD/Unit) by Application (2018-2024)
Table 69. Global Hypertension Drug Price (USD/Unit) by Application (2024-2029)
Table 70. Actelion Ltd. Corporation Information
Table 71. Actelion Ltd. Description and Business Overview
Table 72. Actelion Ltd. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 73. Actelion Ltd. Hypertension Drug Product
Table 74. Actelion Ltd. Recent Developments/Updates
Table 75. Alvogen Corporation Information
Table 76. Alvogen Description and Business Overview
Table 77. Alvogen Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 78. Alvogen Hypertension Drug Product
Table 79. Alvogen Recent Developments/Updates
Table 80. AstraZeneca Plc Corporation Information
Table 81. AstraZeneca Plc Description and Business Overview
Table 82. AstraZeneca Plc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 83. AstraZeneca Plc Hypertension Drug Product
Table 84. AstraZeneca Plc Recent Developments/Updates
Table 85. Bayer AG Corporation Information
Table 86. Bayer AG Description and Business Overview
Table 87. Bayer AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 88. Bayer AG Hypertension Drug Product
Table 89. Bayer AG Recent Developments/Updates
Table 90. Bellerophon Therapeutics, Inc Corporation Information
Table 91. Bellerophon Therapeutics, Inc Description and Business Overview
Table 92. Bellerophon Therapeutics, Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 93. Bellerophon Therapeutics, Inc Hypertension Drug Product
Table 94. Bellerophon Therapeutics, Inc Recent Developments/Updates
Table 95. Boehringer Ingelheim Corporation Information
Table 96. Boehringer Ingelheim Description and Business Overview
Table 97. Boehringer Ingelheim Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 98. Boehringer Ingelheim Hypertension Drug Product
Table 99. Boehringer Ingelheim Recent Developments/Updates
Table 100. Boryung Pharmaceutical Co.,Ltd Corporation Information
Table 101. Boryung Pharmaceutical Co.,Ltd Description and Business Overview
Table 102. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 103. Boryung Pharmaceutical Co.,Ltd Hypertension Drug Product
Table 104. Boryung Pharmaceutical Co.,Ltd Recent Developments/Updates
Table 105. Bristol-Myers Squibb and Company, Corporation Information
Table 106. Bristol-Myers Squibb and Company, Description and Business Overview
Table 107. Bristol-Myers Squibb and Company, Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 108. Bristol-Myers Squibb and Company, Hypertension Drug Product
Table 109. Bristol-Myers Squibb and Company, Recent Developments/Updates
Table 110. Daiichi Sankyo Company Corporation Information
Table 111. Daiichi Sankyo Company Description and Business Overview
Table 112. Daiichi Sankyo Company Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 113. Daiichi Sankyo Company Hypertension Drug Product
Table 114. Daiichi Sankyo Company Recent Developments/Updates
Table 115. Eli Lilly and Company Corporation Information
Table 116. Eli Lilly and Company Description and Business Overview
Table 117. Eli Lilly and Company Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. Eli Lilly and Company Hypertension Drug Product
Table 119. Eli Lilly and Company Recent Developments/Updates
Table 120. F. Hoffmann-La Roche Ltd. Corporation Information
Table 121. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 122. F. Hoffmann-La Roche Ltd. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 123. F. Hoffmann-La Roche Ltd. Hypertension Drug Product
Table 124. F. Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 125. Gilead Sciences, Inc Corporation Information
Table 126. Gilead Sciences, Inc Description and Business Overview
Table 127. Gilead Sciences, Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 128. Gilead Sciences, Inc Hypertension Drug Product
Table 129. Gilead Sciences, Inc Recent Developments/Updates
Table 130. HanAll Biopharma Co., Ltd Corporation Information
Table 131. HanAll Biopharma Co., Ltd Description and Business Overview
Table 132. HanAll Biopharma Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 133. HanAll Biopharma Co., Ltd Hypertension Drug Product
Table 134. HanAll Biopharma Co., Ltd Recent Developments/Updates
Table 135. Hanmi Pharmaceutical Co., Ltd Corporation Information
Table 136. Hanmi Pharmaceutical Co., Ltd Description and Business Overview
Table 137. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 138. Hanmi Pharmaceutical Co., Ltd Hypertension Drug Product
Table 139. Hanmi Pharmaceutical Co., Ltd Recent Developments/Updates
Table 140. Johnson & Johnson Ltd Corporation Information
Table 141. Johnson & Johnson Ltd Description and Business Overview
Table 142. Johnson & Johnson Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 143. Johnson & Johnson Ltd Hypertension Drug Product
Table 144. Johnson & Johnson Ltd Recent Developments/Updates
Table 145. JW Pharmaceutical Corporation (Choongwae Pharma) Corporation Information
Table 146. JW Pharmaceutical Corporation (Choongwae Pharma) Description and Business Overview
Table 147. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 148. JW Pharmaceutical Corporation (Choongwae Pharma) Hypertension Drug Product
Table 149. JW Pharmaceutical Corporation (Choongwae Pharma) Recent Developments/Updates
Table 150. Kyowa Kirin Co., Ltd Corporation Information
Table 151. Kyowa Kirin Co., Ltd Description and Business Overview
Table 152. Kyowa Kirin Co., Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 153. Kyowa Kirin Co., Ltd Hypertension Drug Product
Table 154. Kyowa Kirin Co., Ltd Recent Developments/Updates
Table 155. Lupin Limited Corporation Information
Table 156. Lupin Limited Description and Business Overview
Table 157. Lupin Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 158. Lupin Limited Hypertension Drug Product
Table 159. Lupin Limited Recent Developments/Updates
Table 160. Merck & Co. Corporation Information
Table 161. Merck & Co. Description and Business Overview
Table 162. Merck & Co. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 163. Merck & Co. Hypertension Drug Product
Table 164. Merck & Co. Recent Developments/Updates
Table 165. Noden Pharma DAC Corporation Information
Table 166. Noden Pharma DAC Description and Business Overview
Table 167. Noden Pharma DAC Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 168. Noden Pharma DAC Hypertension Drug Product
Table 169. Noden Pharma DAC Recent Developments/Updates
Table 170. Novartis AG Corporation Information
Table 171. Novartis AG Description and Business Overview
Table 172. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 173. Novartis AG Hypertension Drug Product
Table 174. Novartis AG Recent Developments/Updates
Table 175. Pfizer Inc Corporation Information
Table 176. Pfizer Inc Description and Business Overview
Table 177. Pfizer Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 178. Pfizer Inc Hypertension Drug Product
Table 179. Pfizer Inc Recent Developments/Updates
Table 180. Ranbaxy Laboratories Limited Corporation Information
Table 181. Ranbaxy Laboratories Limited Description and Business Overview
Table 182. Ranbaxy Laboratories Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 183. Ranbaxy Laboratories Limited Hypertension Drug Product
Table 184. Ranbaxy Laboratories Limited Recent Developments/Updates
Table 185. Sanofi S.A Corporation Information
Table 186. Sanofi S.A Description and Business Overview
Table 187. Sanofi S.A Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 188. Sanofi S.A Hypertension Drug Product
Table 189. Sanofi S.A Recent Developments/Updates
Table 190. Lung Biotechnology PBC Corporation Information
Table 191. Lung Biotechnology PBC Description and Business Overview
Table 192. Lung Biotechnology PBC Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 193. Lung Biotechnology PBC Hypertension Drug Product
Table 194. Lung Biotechnology PBC Recent Developments/Updates
Table 195. Nippon Shinyaku Co. Ltd Corporation Information
Table 196. Nippon Shinyaku Co. Ltd Description and Business Overview
Table 197. Nippon Shinyaku Co. Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 198. Nippon Shinyaku Co. Ltd Hypertension Drug Product
Table 199. Nippon Shinyaku Co. Ltd Recent Developments/Updates
Table 200. Novartis AG Corporation Information
Table 201. Novartis AG Description and Business Overview
Table 202. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 203. Novartis AG Hypertension Drug Product
Table 204. Novartis AG Recent Developments/Updates
Table 205. Key Raw Materials Lists
Table 206. Raw Materials Key Suppliers Lists
Table 207. Hypertension Drug Distributors List
Table 208. Hypertension Drug Customers List
Table 209. Hypertension Drug Market Trends
Table 210. Hypertension Drug Market Drivers
Table 211. Hypertension Drug Market Challenges
Table 212. Hypertension Drug Market Restraints
Table 213. Research Programs/Design for This Report
Table 214. Key Data Information from Secondary Sources
Table 215. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hypertension Drug
Figure 2. Global Hypertension Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Hypertension Drug Market Share by Type in 2022 & 2029
Figure 4. Calcium Channel Blockers Product Picture
Figure 5. Diuretics Product Picture
Figure 6. Beta Blockers Vasodilators Product Picture
Figure 7. Angiotensin Converting Enzyme Inhibitors Product Picture
Figure 8. Alpha Blockers Product Picture
Figure 9. Angiotensin Receptor Blockers Product Picture
Figure 10. Renin Inhibitors Product Picture
Figure 11. Global Hypertension Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 12. Global Hypertension Drug Market Share by Application in 2022 & 2029
Figure 13. Hospital
Figure 14. Private Clinic
Figure 15. Others
Figure 16. Global Hypertension Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Hypertension Drug Market Size (2018-2029) & (US$ Million)
Figure 18. Global Hypertension Drug Sales (2018-2029) & (K Units)
Figure 19. Global Hypertension Drug Average Price (USD/Unit) & (2018-2029)
Figure 20. Hypertension Drug Report Years Considered
Figure 21. Hypertension Drug Sales Share by Manufacturers in 2022
Figure 22. Global Hypertension Drug Revenue Share by Manufacturers in 2022
Figure 23. The Global 5 and 10 Largest Hypertension Drug Players: Market Share by Revenue in 2022
Figure 24. Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 25. Global Hypertension Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 26. North America Hypertension Drug Sales Market Share by Country (2018-2029)
Figure 27. North America Hypertension Drug Revenue Market Share by Country (2018-2029)
Figure 28. U.S. Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Canada Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Europe Hypertension Drug Sales Market Share by Country (2018-2029)
Figure 31. Europe Hypertension Drug Revenue Market Share by Country (2018-2029)
Figure 32. Germany Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. France Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. U.K. Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Italy Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Russia Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Asia Pacific Hypertension Drug Sales Market Share by Region (2018-2029)
Figure 38. Asia Pacific Hypertension Drug Revenue Market Share by Region (2018-2029)
Figure 39. China Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Japan Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. South Korea Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. India Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Australia Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Taiwan Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Indonesia Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Thailand Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Malaysia Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Philippines Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Hypertension Drug Sales Market Share by Country (2018-2029)
Figure 50. Latin America Hypertension Drug Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East & Africa Hypertension Drug Sales Market Share by Country (2018-2029)
Figure 55. Middle East & Africa Hypertension Drug Revenue Market Share by Country (2018-2029)
Figure 56. Turkey Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. U.A.E Hypertension Drug Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Global Sales Market Share of Hypertension Drug by Type (2018-2029)
Figure 60. Global Revenue Market Share of Hypertension Drug by Type (2018-2029)
Figure 61. Global Hypertension Drug Price (USD/Unit) by Type (2018-2029)
Figure 62. Global Sales Market Share of Hypertension Drug by Application (2018-2029)
Figure 63. Global Revenue Market Share of Hypertension Drug by Application (2018-2029)
Figure 64. Global Hypertension Drug Price (USD/Unit) by Application (2018-2029)
Figure 65. Hypertension Drug Value Chain
Figure 66. Hypertension Drug Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed